Search our Database of Scientific Publications and Authors

I’m looking for a

    19 results match your criteria Cancer Therapy [Journal]

    1 OF 1

    PML: An emerging tumor suppressor and a target with therapeutic potential.
    Cancer Ther 2009 Sep;7(A):219-226
    Department of Biochemistry, School of Medicine, Case Western Reserve University (CWRU) and the Comprehensive Cancer Center of CWRU. 10900 Euclid Avenue, Cleveland, Ohio 44106, USA.
    Though originally discovered as a tumor suppressor in Acute Promyelocytic Leukemia (APL), the importance of promyelocytic leukemia protein (PML) in cancers of other origins has not been widely studied. Recent studies have shown that multiple types of cancers show decreased expression of PML protein, though the mechanisms leading to this down-regulation are unknown. Decreased expression of PML can result in loss of cell cycle control and prevention of apoptosis and is likely a key event in the promotion of oncogenesis. Read More

    Stress sensor Gadd45 genes as therapeutic targets in cancer.
    Cancer Ther 2009 ;7(A):268-276
    Fels Institute for Cancer Research and Molecular Biology, and Department of Biochemistry, Temple University School of Medicine, Philadelphia, PA, 19140 USA.
    Gadd45 genes have been implicated in stress signaling responses to various physiological or environmental stressors, resulting in cell cycle arrest, DNA repair, cell survival and senescence, or apoptosis. Evidence accumulated up to date suggests that Gadd45 proteins function as stress sensors, mediating their activity through a complex interplay of physical interactions with other cellular proteins that are implicated in cell cycle regulation and the response of cells to stress. These include PCNA, p21, cdc2/cyclinB1, and the p38 and JNK stress response kinases. Read More

    Chemokine signaling in cancer: Implications on the tumor microenvironment and therapeutic targeting.
    Cancer Ther 2009 Apr;7(A):254-267
    Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, University of Kansas Cancer Center; Kansas City, KS 66160.
    Chemokines are soluble factors shown to play important roles in regulating immune cell recruitment during inflammatory responses and defense against foreign pathogens. De-regulated expression and activity of several chemokine signaling pathways have been implicated in cancer progression, including: CCL2, CCL5, CXCL1 and CXCL12. While studies in the past have focused the role of these chemokine signaling pathways in regulating immune responses, emerging studies show that these molecules regulate diverse cellular processes including angiogenesis, and regulation of epithelial cell growth and survival. Read More

    A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors.
    Cancer Ther 2008 ;6(B):955-964
    Department of Immunology, E1040 Biomedical Science Tower, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261.
    Pancreatic and biliary cancers are relatively resistant to chemotherapy and radiation and may therefore provide an opportunity for testing the potential of immunotherapy. MUC1 is an epithelial cell glycoprotein that is highly overexpressed and aberrantly glycosylated in many adenocarcinomas, including pancreatic tumors, providing a tumor specific antigen and target. We performed a Phase I/II clinical trial of a MUC1 peptide-loaded DC vaccine in 12 pancreatic and biliary cancer patients following resection of their primary tumors. Read More

    Analysis of bone marrow plasma cells in patients with solitary bone plasmacytoma.
    Cancer Ther 2009;7:49-52
    Laboratory Oncology Unit ; Ex-Assistant Professor Laboratory Oncology Unit, Dr. B.R.A.IRCH, All India Institute of Medical Sciences, New Delhi, India.
    Local radiotherapy is the treatment of choice for solitary bone plasmacytoma (SBP) and the role of adjuvant systemic chemotherapy in preventing progression to multiple myeloma (MM) is controversial. The purpose of this study was to examine the presence of systemic disease in the form of neoplastic plasma cells (PC) in bone marrow of patients with SBP. Flow cytometric immunophenotyping of PC was carried out on bone marrow aspirate of 7 patients using monoclonal antibodies: CD19 FITC, CD45 FITC, CD20 FITC, CD52 PE, CD117 PE, CD56 PE, CD38 PerCP-Cy5. Read More

    Phage L5 integrating vectors are present within the Mycobacterial Cell in an equilibrium between integrated and excised states.
    Cancer Ther 2009 Jan;7:35-42
    Basic Medical Sciences, College of Osteopathic Medicine, Western University of Health Sciences, 309 E. Second St. Pomona CA 91766.
    Integrating mycobacterial plasmids containing the phage L5 attachment site (attP) are able to insert into the mycobacterial chromosome attB site. Plasmids containing the attP site and chromosome containing the attB site are present in equilibrium between the inserted and the excised states in the presence of the phage L5 integrase. Read More

    siRNA Down-regulation of the PATZ1 Gene in Human Glioma Cells Increases Their Sensitivity to Apoptotic Stimuli.
    Cancer Ther 2008 ;6(B):865-876
    Brain Tumor Program, Sidney Kimmel Cancer Center, San Diego, CA 92121.
    The PATZ1 gene encodes a transcription factor that belongs to the BTB/POZ group of transcriptional regulators and has been implicated as a transcriptional repressor. We cloned cDNA from glioma cell lines and found they expressed transcript variant 2 of PATZ1. We designed a specific siRNA against PATZ1 and showed that this siRNA, but not a control randomized siRNA, reduced PATZ1 expression in glioma cells as determined by quantitative PCR. Read More

    Disruption of Survivin in K562 cells elevates telomerase activity and protects cells against apoptosis induced by the Bcr-abl kinase inhibitor STI571.
    Cancer Ther 2008 ;6(B):603-610
    Department of Microbiology & Immunology, and the Walther Oncology Center, Indiana University School of Medicine, Indianapolis, IN 46202.
    The Bcr-abl kinase inhibitor STI571 produces clinical responses in most patients with Chronic Myeloid Leukemia (CML); however, development of resistance limits utility. One strategy to overcome STI571 resistance is to decrease the level/activity of Bcr-abl. We reported that disruption of the anti-apoptotic protein Survivin promoted STI571-induced apoptosis in Bcr-abl(+) K562 cells, through caspase-dependent Bcr-abl degradation. Read More

    Thiazolidinediones as anti-cancer agents.
    Cancer Ther 2008 ;6(A):25-34
    Department of Medicine, Emory University and Atlanta Veterans Affairs Medical Centers, Atlanta, GA 30033.
    The PPAR-gamma (PPAR-γ) activating thiazolidinedione (TZD) medications are a class of drugs used to improve lipid and glucose metabolism in type-2 diabetes. In addition to their known insulin sensitization action, these drugs have been shown to suppress tumor development in several in vitro and in vivo models. Among the proposed mechanisms for the anti-tumor effects of TZDs, apoptosis induction, cell cycle arrest, and differentiation have been extensively reported. Read More

    From here to eternity - the secret of Pharaohs: Therapeutic potential of black cumin seeds and beyond.
    Cancer Ther 2008 ;6(b):495-510
    Department of Pathology and Division of Internal Medicine, Barbara Ann Karmanos Cancer Institute, Wayne State University, School of Medicine, Detroit, MI- 48201, USA.
    Over many centuries humans have been mining the bounties of nature for discovering substances that have been used for the treatment of all human diseases; many such remedies are useful even today as modern day medicine. Emerging evidence also suggests that the search is still continuing for harnessing active compounds from nature in combating human illnesses although pharmaceutical industries are equally active for synthesizing small molecule compounds as novel therapeutics. The lesson learned over many centuries clearly suggests that further sophisticated search for finding compounds from natural resources together with robust characterization and chemical synthesis will lead to the discovery of novel drugs that may have high therapeutic efficacy against all human diseases including cancer. Read More

    Pre-treatment with a non-therapeutic dose of cisplatin increases solid tumour response to liposomal-p53 gene therapy- An in vivo study.
    Cancer Ther 2004 ;2:239-244
    School of Biomedical Science, Charles Sturt University, P.O. Box 588, Wagga Wagga 2678, Australia.
    Successful liposomal-mediated gene therapy is often limited by poor transfection efficiencies. One method previously shown to increase the efficiency of liposomal gene delivery is through the administration of a non-therapeutic dose of the chemotherapeutic drug cisplatin prior to lipofection. The currents study aims to utilise this method to deliver lipoplexes containing the p53 tumour suppressor gene with the aim of increasing therapeutic effect of the p53 gene on a solid tumour in vivo. Read More

    Suppression of breast cancer metastasis through the inhibition of VEGF-mediated tumor angiogenesis.
    Cancer Ther 2007 ;5:273-286
    Department of Pathology and Department of Medicine, University of Tennessee Health Science Center, Memphis, TN.
    One of the major causes of failure in the treatment of breast cancer is the occurrence of metastasis, the spreading of the primary tumor to distant organs. It is thus important to intervene at a key step of metastatic process, such as angiogenesis, for effective breast cancer treatment. Vascular endothelial growth factor (VEGF) plays a pivotal role in tumor angiogenesis. Read More

    Neutrophil gelatinase-associated lipocalin: new paths for an old shuttle.
    Cancer Ther 2007 ;5(B):463-470
    Nephrology and Hypertension, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, OH, USA.
    Neutrophil Gelatinase-Associated Lipocalin (NGAL) is a lipocalin that is well known for its functions as a shuttle for iron and siderophores, which comprises a critical component of innate immunity to exogenous bacterial infections. However, several lines of recent evidence have added new dimensions of functionality that have attracted the interest of cancer biologists and oncologists. This review will highlight the exciting new paths and roles that are emerging for NGAL in human cancers, in the tissue response to anticancer therapy, and in the acute kidney injuries that commonly complicate the care of patients with cancer. Read More

    Cisplatin nephrotoxicity: molecular mechanisms.
    Cancer Ther 2003 ;1:47-61
    Department of Cell Biology, University of Oklahoma Health Sciences Center.
    Cisplatin is one of the most widely used chemotherapeutic agents for the treatment of several human malignancies. The efficacy of cisplatin is dose dependent, but the significant risk of nephrotoxicity frequently hinders the use of higher doses to maximize its antineoplastic effects. Several advances in our understanding of the biochemical and molecular mechanisms underlying cisplatin nephrotoxicity have recently emerged, and are reviewed in this article. Read More

    Novel peptides from the RAS-p21 and p53 proteins for the treatment of cancer.
    Cancer Ther 2007 ;5B:331-344
    Department of Surgery, New York Harbor VA Medical Center, 800 Poly Place, Brooklyn, NY 11209.
    We have employed a novel computer-based molecular modeling method to design peptides from the ras-p21 and p53 proteins that block proliferation of cancer cells. The rationale of our approach is to identify peptide domains from each protein that alter conformation in response to oncogenic amino acid substitutions in their polypeptide chain. We accomplish this by first generating and comparing low energy average structures for oncogenic and wild-type proteins using conformational energy calculations. Read More

    Chemotherapy in Androgen-Independent Prostate Cancer (AIPC): What's next after taxane progression?
    Cancer Ther 2007 ;5A:151-160
    Medical Oncology Branch, National Cancer Institute, National Institutes of Health.
    SummaryProstate cancer is the most common non-cutaneous cancer in the United States. Although most are diagnosed at earlier stages of disease, a significant number of patients will eventually progress to metastatic androgen-independent prostate cancer (AIPC) and will receive chemotherapy. The benefit of chemotherapy in overall survival has been demonstrated in studies utilizing docetaxel. Read More

    Needle-like morphology of H2K4b polyplexes associated with increases in transfection in vitro.
    Cancer Ther 2007 Jun;5B:193-202
    Department of Pathology, University of Maryland Baltimore, School of Medicine, Baltimore, Maryland.
    SUMMARY: Several synthetic histidine-lysine (HK) polymers have been screened for their efficacy as carriers of nucleic acids in vitro. One branched HK polymer, H2K4b (and its derivatives), has been particularly effective as an in vitro carrier of plasmids. In this study, we investigated whether various salt conditions during formation of the H2K4b/plasmid DNA polyplex affected transfection. Read More

    Advantages of a unique DNA-based vaccine in comparison to paclitaxel in treatment of an established intracerebral breast cancer in mice.
    Cancer Ther 2006 ;4A:163-170
    In this study we compared the benefits of treating C3H/He mice with an established intracerebral breast carcinoma by immunization with a unique DNA-based vaccine to chemotherapy with paclitaxel. Prior studies revealed the immunotherapeutic properties of a vaccine prepared by transfer of genomic DNA from breast cancer cells into a highly immunogenic cell line. Here, C3H/He mice with an established intracerebral breast cancer were treated either by injection into the tumor bed through a unique cannula system with the cell based vaccine or with paclitaxel administered intraperitoneally. Read More

    Glioma cell integrin expression and their interactions with integrin antagonists: Research Article.
    Cancer Ther 2005 ;3A:325-340
    A panel of human glioma cell explants was screened for integrin expression by flow cytometry using α(ν)β-specific antibodies. A lower percentage of the glioma cells were positive for the α(ν)β3 (mean % positive = 20.8%) integrin, whereas higher percentages were positive for the ανβ5 (mean % positive = 72. Read More

    1 OF 1